

1 **A protocol for high-dose quadrivalent influenza vaccine**  
2 **effectiveness in the community and long-term care facilities**  
3 **using electronic health records**

4 **Short title: High-dose quadrivalent influenza vaccine effectiveness in the**  
5 **community and long-term care facilities protocol**

6  
7

8 **Authors:** Patrícia Soares<sup>1</sup>, Verónica Gomez<sup>1</sup>, Vânia Gaio<sup>1</sup>, João Almeida Santos<sup>1</sup>, Ana Paula  
9 Rodrigues<sup>1</sup>, Ausenda Machado<sup>1</sup>

10 <sup>1</sup> National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal

11

12 **Funding:** This work was partially supported by FCT – Fundação para a Ciência e Tecnologia, I.P.  
13 by project reference CEECINST/00049/2021/CP2817/CT0001 and DOI identifier  
14 10.54499/CEECINST/00049/2021/CP2817/CT0001.

15

16

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 17 **Abstract**

18 Since the 2022-2023 season in Portugal, a high-dose quadrivalent influenza vaccine is freely  
19 available for individuals living in long-term care facilities (LTCF). In 2024-2025, vaccination was  
20 extended to community-dwelling individuals aged  $\geq 85$  years. Given the scarcity of reported high-  
21 dose influenza vaccine effectiveness (IVE) estimates for this population, this study aims to  
22 estimate the high-dose relative and absolute IVE.

23 A retrospective cohort study using data from electronic health records databases (EHR) will be  
24 implemented, using two cohorts, one of individuals vaccinated with influenza vaccine (to  
25 estimate relative IVE) and another of individuals eligible for the high-dose quadrivalent influenza  
26 vaccine (to estimate absolute IVE). We will consider two subgroups for both cohorts: individuals  
27 living in LTCF and community-dwelling individuals aged  $\geq 85$ . We will use a fixed cohort approach,  
28 defining the eligible population by age at the vaccination campaign(s) start and living status. The  
29 outcomes are based on the primary cause of hospital admission. The reference population  
30 database will be defined by linking EHR on vaccination, comorbidities, and hospitalisations using  
31 a unique identifier through a deterministic data linkage procedure, and influenza vaccination  
32 status will be assessed retrospectively. We will use Cox proportional hazards regression models  
33 to estimate the hazard ratio (HR), considering as event the first hospitalisation due to influenza-  
34 like-illness and as exposure the vaccination status. IVE will be estimated as one minus the  
35 confounder-adjusted HR of vaccinated with the high-dose quadrivalent influenza vaccine vs  
36 vaccinated with standard dose (to estimate relative IVE) or unvaccinated (to estimate absolute  
37 IVE).

38 While challenges such as EHR constraints and potential reporting bias pose limitations, using  
39 routinely collected data has successfully estimated COVID-19 VE and enables precise monitoring

40 of VE with higher representativeness. The results of this study will inform the Health Ministry on  
41 the future influenza vaccine programme in Portugal.

## 42 **Keywords**

43 Quadrivalent Influenza Vaccine, Vaccine Effectiveness, Electronic Health Records, Portugal, Long-  
44 Term Care Facilities

45

## 46 **Background**

47 In Portugal, as in most European countries, influenza seasonal immunisation is recommended  
48 annually to high risk individuals, which include, among others, elderly individuals (age  
49 stratification varies across seasons, i.e., aged  $\geq 60$  or aged  $\geq 65$  years) and those who reside in  
50 long-term care facilities (LTCF)(1).

51 Adults aged 65 or more are more prone to lower respiratory tract infections, including  
52 pneumonia, bronchitis, and tracheobronchitis, due to specific factors, such as genetic  
53 polymorphisms, chronic immunocompromised conditions, age and correspondent age-related  
54 comorbidities, that may compromise the individual capacity to produce an adequate immune  
55 response(2,3). These infections are associated with considerable morbidity and can lead to  
56 hospitalisation, especially in frail older adults, such as those residing in LTCF (4). There is a  
57 potentially different risk of exposure in older community-dwelling individuals due to the greater  
58 number of contacts. Additionally, LTCFs significantly contribute to the variability in exposure to  
59 the disease between individuals, resulting in greater individual susceptibility to severe outcomes  
60 (4,5).

61 Vaccination is widely considered the most effective intervention against influenza and its  
62 associated complications (5). However, influenza vaccination strategies might target individuals  
63 who, although at high risk of influenza complications, may have impaired capacity for developing  
64 effective vaccine-induced immunity. Given the specificities of individuals in LTCF, the effect of  
65 influenza vaccination in this population needs further investigation (2,5). A high-dose  
66 quadrivalent influenza vaccine was developed to provide greater protection and better prevent  
67 influenza-related complications than the standard dose influenza vaccine.

68 This high-dose quadrivalent vaccine presented higher efficacy in a randomised clinical trial versus  
69 a standard-dose influenza vaccine for preventing laboratory-confirmed influenza illness in adults  
70 aged 65 or more (3). Systematic reviews and meta-analyses, which included randomised and  
71 observational studies, assessed the effectiveness of high-dose inactivated influenza vaccines  
72 versus standard-dose influenza vaccines against influenza-related outcomes in 65 or more years  
73 old individuals (6,7). The results support the evidence on the effectiveness of high-dose  
74 inactivated influenza vaccines compared to standard-dose influenza vaccines in preventing  
75 severe influenza outcomes in 65 or more years old individuals, with additional support from  
76 observational data (7). Regarding severity-related outcomes, the high-dose quadrivalent  
77 influenza vaccine was more effective than the standard-dose influenza vaccine in preventing  
78 influenza-related hospitalisations, with a relative influenza vaccine effectiveness (rIVE) of 11.2%  
79 (7.4%-14.8%) for all seasons. Despite the important evidence of the effectiveness of the influenza  
80 vaccine (IVE) of the high-dose inactivated influenza vaccines for individuals aged 65 or older, only  
81 three studies in nursing homes were included (6). Review studies indicated a need for further  
82 real-world population-based studies of high-dose influenza vaccines. Hence, it remains necessary  
83 to assess the clinical effectiveness of this vaccine in older adults living in LTCF (7–9).

84 In Portugal, since the 2022-2023 season (1,10), the high-dose quadrivalent influenza vaccine is  
85 available exclusively for individuals aged 65 or more living in LTCF, free of charge. In the 2023-24  
86 season, the high-dose influenza vaccine became available to community-dwelling individuals  
87 aged 65 or more in community pharmacies, with co-payment if the patient presents a  
88 prescription (11).

89 Given the scarcity of reported high-dose IVE estimates for this population and the Portuguese  
90 strategy of vaccinating institutionalised individuals aged 65 or more, it is crucial to evaluate the  
91 vaccine's effect on preventing severe outcomes in this age group of the Portuguese population.  
92 Thus, the objective of this study is to estimate the rIVE of the high-dose quadrivalent influenza  
93 vaccine against hospital admission due to influenza-like-illness in individuals vaccinated with any  
94 influenza vaccine and the absolute IVE of the high-dose quadrivalent influenza vaccine against  
95 hospital admission due to influenza-like-illness in individuals eligible for the high-dose  
96 quadrivalent vaccine, using data routinely collected in electronic health records (EHR) in  
97 mainland Portugal.

98

## 99 **Methods**

### 100 **Study design and population**

101 A retrospective cohort study using data collected routinely in EHR databases will be  
102 implemented. For the estimation of rIVE, only vaccinated individuals will be included, either with  
103 the high-dose or the standard influenza vaccine. For the estimation of absolute IVE, individuals  
104 eligible for the high-dose influenza vaccine during the study period will be included. For both

105 cohorts, we will consider two subgroups: community-dwelling individuals aged  $\geq 85$  years and  
106 individuals living in LTCF. The cohorts are represented in Figure 1, with panel A representing rIVE  
107 and panel B absolute IVE.

108

109

110 **Figure 1:** Diagram of the two cohorts designed in this study. A – cohort of vaccinated individuals  
111 to measure relative influenza vaccine effectiveness, B – cohort of individuals eligible for the high-  
112 dose influenza vaccine to measure absolute influenza vaccine effectiveness. For the two cohorts,  
113 we will consider two subgroups: community-dwelling individuals aged  $\geq 85$  years and individuals  
114 living in LTCF.

115

116

117 We will use a fixed cohort approach, defining the eligible population by their age at the start of  
118 the vaccination campaign(s) and living status. Table 1 describes the connection between the  
119 cohorts and the objectives.

120

121 **Table 1.** Summary of the study design with the different cohorts, objectives and exposed and  
122 unexposed groups

Cohort	Subgroup	Objective	Exposed	Reference group
Vaccinated individuals	Individuals living in LTCF	Estimate relative IVE of the high-	Vaccinated with high-dose	Vaccinated with standard

(Figure 1, panel A)	Individuals living in the community (≥85 years)	dose quadrivalent influenza vaccine	quadrivalent influenza vaccine	influenza vaccine
Individuals eligible for influenza vaccination (Figure 1, panel B)	Individuals living in LTCF	Estimate absolute IVE of the high-dose quadrivalent influenza vaccine	Vaccinated with high-dose quadrivalent influenza vaccine	Unvaccinated individuals eligible for the high-dose quadrivalent influenza vaccine
	Individuals living in the community (≥85 years)			

123 IVE – influenza vaccine effectiveness; LTCF – long-term care facilities

124

## 125 Inclusion and exclusion criteria

126 The study population includes all registered individuals without contraindications for influenza  
 127 vaccination residents in mainland Portugal. Only vaccinated individuals with the high-dose  
 128 quadrivalent or standard influenza vaccine living in LTCF or community-dwelling individuals aged  
 129 85 or older will be included to estimate rIVE. Whereas, to estimate absolute IVE, only eligible  
 130 individuals for the high-dose influenza vaccine living in LTCF or community-dwelling individuals  
 131 aged 85 or older will be included.

132 We will exclude individuals with inconsistent or missing data on vaccination (e.g. any vaccination  
 133 date unknown and any vaccine brand unknown), individuals who received any vaccine brand not

134 approved by the European Medicines Agency (EMA), and individuals vaccinated before the study  
135 started.

## 136 **Study setting and period**

137 To estimate rIVE, the study population will include individuals vaccinated with the high-dose or  
138 standard influenza vaccine in mainland Portugal between the 2022/2023 and 2024/2025  
139 seasons. When applicable, we will analyse each season (2022/2023, 2023/2024, 2024/2025)  
140 individually, starting after the implementation of each influenza vaccination campaign and  
141 ending nine months thereafter.

142 To estimate absolute IVE, the study population will include individuals for whom the high-dose  
143 influenza vaccine has been recommended in mainland Portugal for the 2024/2025 season. The  
144 study period will start after the implementation of the influenza vaccination campaign period  
145 and end nine months thereafter.

## 146 **Vaccination status**

147 To estimate rIVE, the vaccination status will be assessed retrospectively, and the time since  
148 vaccination will be estimated. The exposure of interest will be to receive the high-dose  
149 quadrivalent influenza vaccine, and the comparison group will be composed of those who  
150 received the standard-dose influenza vaccine.

151 To estimate absolute IVE, the vaccination status will be assessed as a time-changing variable  
152 according to the following classification:



- 153       ○ Unvaccinated: person-time of individuals without any quadrivalent influenza vaccine in  
154       the season.
- 155       ○ Vaccinated: person-time of individuals who received a high-dose quadrivalent influenza  
156       vaccine dose during the study period. The completion status is achieved 14 days after  
157       administration of the dose.

## 158   **Time since vaccination**

159   If the sample size allows it, the time since completion of the high-dose influenza vaccine will be  
160   analysed as a secondary objective. For the rIVE estimation, time since vaccination will be  
161   considered a confounder to add to the model. For the absolute IVE estimation, time since  
162   vaccination will be calculated at each time point and classified into the following categories:

- 163       • From time 14 days to ≤89 days after time 0 (i.e., <13 weeks, approximately 3 months);  
164       • 90 to 179 days after time 0 (i.e., ≥13 weeks and <26 weeks, approximately 3 to 6 months);  
165       • 180 to 272 days (i.e., ≥26 weeks and <39 weeks, approximately 6 to 9 months).

## 166   **Outcome**

167   The outcomes of interest are defined based on the primary cause of admission to a hospital,  
168   coded according to ICD-10: J11 (Influenza with pneumonia), J12 (Viral pneumonia) and J18  
169   (Pneumonia of unknown aetiology).

170   As a secondary outcome, we will also analyse cardiorespiratory hospitalisations as a primary  
171   cause of admission, with a secondary diagnosis of pneumonia (flu, viral or unknown aetiology).

172   Each of these outcomes will be analysed separately. The outcome date will correspond to the  
173   hospitalisation date. Details on the ICD-10 codes are available in Supplementary Table S1.

## 174 **Stratification variables**

175 If possible, and when applicable, rIVE will be estimated for each seasonal campaign.

## 176 **Potential confounding variables for adjustment**

177 A set of variables will be used to account for confounding bias. Sociodemographic variables, such  
178 as sex, age, health administrative region, and the European Deprivation Index, will be used as  
179 potential confounding factors. We will also consider the vaccination against COVID-19 in the  
180 previous season to account for health-seeking behaviours. The presence of chronic conditions,  
181 such as diabetes, asthma, or other chronic respiratory diseases, cancer, chronic renal disease,  
182 hypertension or other chronic cardiovascular disease, obesity, chronic hepatic disease,  
183 neuromuscular disease, and immunodeficiency, will also be included as potential confounding  
184 factors.

## 185 **Data sources**

186 The study will use routinely collected data from various population health registries. Each  
187 database will contain a unique identifier for each individual to allow data linkage between  
188 databases.

189 The National Health Service User (NHSU) dataset is the reference population database and  
190 includes individual records of the target study population. For this study, we will only consider  
191 individuals who had contact with the NHSU healthcare system three years before the start of the  
192 study period.

193 Vaccination registry or vaccination record databases with individual data, including influenza and  
194 vaccine brand dates, will be provided by the National Vaccination Registry – VACINAS.

195 Regarding the outcome, the National Hospital Discharges Registry will be used to assess  
196 hospitalisation information. We will also use data on mortality, which will be extracted from the  
197 National Death Registry, with the respective date of death.

## 198 **Construction of the cohort**

### 199 **Identification of individuals and characteristics at baseline**

200 The reference population database will be linked with the electronic databases on vaccination,  
201 comorbidities and/or health-seeking behaviours, hospitalisations and other vital registries, using  
202 the unique identifiers through a deterministic data linkage procedure (no random component in  
203 the linkage procedure). Individuals will enter the study in their corresponding vaccination status  
204 group based on the data available in the vaccination registry.

205 Variables to be measured at baseline include age, sex, health administrative region,  
206 comorbidities, and other socioeconomic or health-seeking behaviour variables that will be used  
207 to adjust IVE estimates to stratify or account for confounding.

### 208 **Time-changing characteristics (to estimate absolute IVE)**

209 Vaccination status and time since vaccination will be assessed, and individuals will be classified  
210 into the same or updated vaccination status daily, generating a new record in the dataset for  
211 each new assessment. Person-time exposure between 0 and 13 days after vaccination will be  
212 excluded from the analysis.

## 213 **Identification of outcomes during follow-up**

214 Information for identifying outcomes and the dates when they occurred will be obtained by data  
215 linkage between the cohort built previously and the databases containing information on the  
216 respective outcomes. Outcome classification for each individual will be assessed from the start  
217 of the vaccination campaign.

## 218 **Censoring events**

219 All individuals will be followed from the start of the vaccination campaign until:

- 220 ○ Hospitalisation date (corresponding to the event date);
- 221 ○ At the end of the study (nine months after the start of the vaccination campaign);
- 222 ○ On the date of death (any cause).

## 223 **Analysis plan**

### 224 **Description of the sample selection**

225 The total number of individuals fulfilling the inclusion criteria at the study baseline will be  
226 calculated for each cohort. The number and proportion of individuals excluded after applying  
227 each selection criteria will be recorded.

### 228 **Description of the study population**

229 The number of persons, total person-time of follow-up, and the number of events by vaccination  
230 status will be calculated. Distribution of the number of persons and total person-time of follow-  
231 up will be described by baseline variables in each vaccination status group considered in the

232 study. To estimate the total number of persons, we will consider the vaccination status group at  
233 the end of each person-time follow-up (to estimate absolute IVE).

234 The proportion of the missing data will be used to determine if each specific variable can be  
235 included in the model and how (e.g., missing could eventually be included in the model as a  
236 category). Imputation to address missingness is not planned as a means for increasing data  
237 quality.

### 238 **Estimation of the vaccine effectiveness**

239 A complete case analysis will be performed considering all variables in the final model to estimate  
240 adjusted-confounding IVE.

241 We will use Cox proportional hazards regression models to estimate the hazard ratio (HR),  
242 considering the event the first hospitalisation due to influenza-like-illness and as exposure the  
243 vaccination status. The crude HR of vaccinated with the high-dose influenza vaccine vs vaccinated  
244 with the standard dose (rIVE) or unvaccinated (absolute IVE) will be estimated for each outcome  
245 of interest during the study period, without adjusting for other factors or covariates.

246 We will consider two sets of confounding factors. First, we will estimate partially adjusted HR,  
247 adjusting by age, sex and country region. Age will be modelled using a restricted cubic spline,  
248 with knots specified according to Harrell (12). Second, a fully adjusted HR estimate will be  
249 produced by adjusting variables related to socioeconomic condition, comorbidities and health-  
250 seeking behaviour. IVE will be estimated as one minus the confounder-adjusted HR of vaccinated  
251 vs vaccinated with the standard dose (rIVE) or unvaccinated (absolute IVE) for each outcome of  
252 interest.

253  $IVE = (1 - aHR) * 100$

254 To estimate relative IVE, the time since vaccination will be modelled using a restricted cubic  
255 spline, with knots specified at zero and 15 days and then at the 40<sup>th</sup> and 90<sup>th</sup> percentile. To  
256 estimate absolute IVE for the time since vaccination (secondary objective), IVE will be estimated  
257 by comparing the hazard rate of the outcome in individuals vaccinated with the high-dose  
258 influenza vaccine for each class of the time since vaccination - 14 to 89 days, 90 to 179 days and  
259 180 to 272 days (exposed group), in comparison with the outcome hazard rate in unvaccinated  
260 individuals (reference group).

## 261 **Propensity score matching**

262 Individual characteristics might influence vaccination status, leading to systematic differences  
263 between those vaccinated with different vaccines and those vaccinated (rIVE) and unvaccinated  
264 (absolute IVE). Propensity score matching is a statistical technique used to reduce selection bias  
265 in observational studies by creating a matched set of treated (vaccinated with high-dose  
266 influenza vaccine) and untreated (vaccinated – rIVE and unvaccinated – absolute IVE) individuals  
267 with similar propensity scores. The first option will be matching without replacement, 1-to-1.  
268 However, considering the coverage vaccination, this ratio might need to be reviewed.

269 Several assumptions should be met to ensure that conditioning on the propensity score will lead  
270 to unbiased estimates of average treatment effects. The first one is that there should not be  
271 unmeasured confounders, i.e. the variables affecting vaccination status and hospitalisation due  
272 to influenza-like-illness should have been measured. The second relates to positivity, each  
273 individual should have a non-zero probability of getting the high-dose influenza vaccine.  
274 Additionally, the propensity score model should be correctly defined, and there should not be  
275 any interference between individuals, i.e., an individual vaccinated with the high-dose influenza

276 vaccine will not affect the hospitalisation of another individual. This final assumption has  
277 implications in estimating absolute IVE studies due to herd immunity since vaccinated individuals  
278 could indirectly protect unvaccinated individuals, leading to IVE underestimation. To account for  
279 potential violations of this assumption, we will consider statistical methods that account for  
280 clustering, which could be the geographical region of residence.

281 The propensity score will be estimated using logistic regression, where the vaccination status will  
282 be the outcome, and the baseline individual characteristics will be used to adjust. Then, the  
283 vaccinated with high-dose influenza vaccine and vaccinated (rIVE) or unvaccinated (absolute IVE)  
284 individuals with similar propensity scores will be matched, using nearest neighbour matching,  
285 and compared to ensure the balance of covariates. Once the balanced dataset is obtained, the  
286 Cox proportional hazards regression model will be used, with the adjustments mentioned in the  
287 section above to adjust for residual confounding (13).

## 288 **Ethics**

289 This protocol was submitted to the National Institute of Health Doutor Ricardo Jorge Ethics  
290 Committee (INSA-EC) in 2024 July 19<sup>th</sup> and approved on July 30<sup>th</sup>.

## 291 **Discussion**

292 This article outlines the conceptual framework and methodological approach to estimate high-  
293 dose quadrivalent IVE using EHR in the community and LTCF. We intend to estimate the risk of  
294 hospitalisation reduction by comparing two vaccination strategies (High-dose quadrivalent  
295 influenza vaccine and standard-dose influenza vaccine – rIVE), and comparing vaccinated with  
296 unvaccinated individuals (absolute IVE). To date, retrospective cohort studies regarding high-

297 dose quadrivalent IVE in reducing influenza-related hospitalisation of individuals aged 65 or older  
298 have been conducted using specific populations, such as United States veterans or health  
299 insurance beneficiaries (10–13). To the best of our knowledge, studies on the effect of high-dose  
300 influenza vaccines in LTCF remain limited to immunogenicity studies.

301 Given the population under study, LTCF and community-dwelling individuals ( $\geq 85$  years), the  
302 potential low vaccine coverage in the eligible population, and the absence of specific studies  
303 designed to collect data in LTCF settings, we decided to use routinely collected data in electronic  
304 health registries to estimate the high-dose quadrivalent IVE. This approach has already been used  
305 successfully to estimate COVID-19 VE (14), and allows VE monitoring with good precision and  
306 high representativeness(15–18).

307 Despite its strengths, this study also has some limitations. We plan to use EHR, which does not  
308 aim to collect data for research purposes. Thus, this could lead to misclassification bias regarding  
309 vaccine status, outcomes, and confounding variables. For this reason, we might be unable to  
310 control for residual confounding since many relevant variables are not monitored or available in  
311 registries, and one should be aware that estimates can vary in the presence of confounding.  
312 Additionally, unvaccinated individuals will be the reference group when estimating absolute IVE.  
313 However, these individuals might differ from the vaccinated individuals due to their clinical  
314 profile or possible misclassification bias. Thus, we will use propensity score matching to account  
315 for this, assigning a probability of being vaccinated to each individual based on covariates.  
316 Considering that we will use EHRs, we might also be unable to correctly identify all individuals  
317 living in LTCF, as the report might vary geographically and temporally. Additionally, identifying  
318 these individuals might be associated with a differential bias, assuming that vaccinated



319 individuals might be more likely to be reported as living in LTCF than unvaccinated. This situation  
320 is less likely to be problematic when estimating relative and absolute IVE in the community.

321 Another limitation is the potential outcome misclassification. In VE studies, it is extremely  
322 important to have sensible outcome definitions as the vaccines are designed to protect against  
323 influenza and related complications and studies use laboratory-confirmed outcomes. Using  
324 specific influenza ICD codes to identify severe influenza could underestimate severe influenza as  
325 the diagnosis is highly dependent on the testing strategy and, thus, on the codification attributed  
326 at discharge. On the other hand, including a broader range of ICD codes in the outcome definition  
327 could also underestimate IVE by including non-influenza-related outcomes. To balance this, we  
328 intend to use ICD codes that have been used for a long time in influenza surveillance and are  
329 highly sensitive. Finally, we intend to use discharge codes, as they are the final primary diagnosis  
330 of the hospitalisation. However, there are delays in hospital discharge and the codification of the  
331 hospitalisation event. In order to minimise this, the retrospective study will only use end-of-  
332 season data.

333 In conclusion, the study aims to produce estimates of high-dose IVE in the population eligible for  
334 the high-dose vaccine and contribute to the overall knowledge of the potential added protection  
335 provided by this vaccine. Given the vaccination strategy implemented in this population and the  
336 national effort in acquiring and implementing vaccination strategies, evaluating the effect of such  
337 public health intervention is crucial. The results will also inform decision-makers in future IVE.  
338 Additional future studies should include, not only relative indicators, but also quantitative  
339 measures of the vaccination strategy's impact on the population (19).

340

## 341 Authors' contributions

342 PS and AM conceptualised and designed the study. AM, PS and VG wrote the first draft of the  
343 protocol. APR, VG, JAS provided technical inputs. All authors revised and approved the final  
344 version.

## 345 References

- 346 1. Direção-Geral de Saúde. Campanha de Vacinação Sazonal contra a Gripe: Outono-Inverno  
347 2024-2025. 2024;
- 348 2. Gravenstein S, Davidson HE, Taljaard M, Ogarek J, Gozalo P, Han L, et al. Comparative  
349 effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US  
350 nursing home residents admitted to hospital: a cluster-randomised trial. *Lancet Respir*  
351 *Med* [Internet]. 2017;5(9):738–46. Available from: [http://dx.doi.org/10.1016/S2213-](http://dx.doi.org/10.1016/S2213-2600(17)30235-7)  
352 [2600\(17\)30235-7](http://dx.doi.org/10.1016/S2213-2600(17)30235-7)
- 353 3. Diaco M, Chang LJ, Seet B, Robertson CA, Chit A, Mercer M, et al. Introductory paper: High-  
354 dose influenza vaccine. *Vaccine* [Internet]. 2021;39:A1–5. Available from:  
355 <https://doi.org/10.1016/j.vaccine.2020.09.005>
- 356 4. Furman CD, Rayner A V., Tobin EP. Pneumonia in older residents of long-term care  
357 facilities. *Am Fam Physician*. 2004;70(8):1495–500.
- 358 5. Gozalo PL, Pop-Vicas A, Feng Z, Gravenstein S, Mor V. Effect of influenza on functional  
359 decline. *J Am Geriatr Soc*. 2012;60(7):1260–7.
- 360 6. Lee JKH, Lam GKL, Yin JK, Loiacono MM, Samson SI. High-dose influenza vaccine in older  
361 adults by age and seasonal characteristics: Systematic review and meta-analysis update.

- 362 Vaccine X [Internet]. 2023;14(June 2022):100327. Available from:  
363 <https://doi.org/10.1016/j.jvacx.2023.100327>
- 364 7. Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and effectiveness of  
365 high-dose influenza vaccine in older adults by circulating strain and antigenic match: An  
366 updated systematic review and meta-analysis. Vaccine [Internet]. 2021;39:A24–35.  
367 Available from: <https://doi.org/10.1016/j.vaccine.2020.09.004>
- 368 8. Robison SG, Thomas AR. Assessing the effectiveness of high-dose influenza vaccine in  
369 preventing hospitalization among seniors, and observations on the limitations of  
370 effectiveness study design. Vaccine [Internet]. 2018;36(45):6683–7. Available from:  
371 <https://doi.org/10.1016/j.vaccine.2018.09.050>
- 372 9. Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative Effectiveness of  
373 Influenza Vaccines among the United States Elderly, 2018-2019. J Infect Dis.  
374 2020;222(2):278–87.
- 375 10. DGS - Direção Geral da Saúde, Direção Geral de Saúde, Machado A. Campanha de  
376 Vacinação Sazonal contra a Gripe: Outono-Inverno 2022-2023. 2023;(January):1–9.  
377 Available from: [https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-](https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-n-0072022-de-02092022-pdf.aspx)  
378 [circulares-normativas/norma-n-0072022-de-02092022-pdf.aspx](https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-n-0072022-de-02092022-pdf.aspx)
- 379 11. Direção Geral de Saúde. Norma de Orientação Clínica nº 006/2023: Campanha de  
380 Vacinação Sazonal contra a Gripe: Outono- Inverno 2023-2024. 2023;1–12.
- 381 12. FE. H. Regression modeling strategies: with applications to linear models, logistic  
382 regression, and survival analysis. New York: Springer; 2001. 568 p.
- 383 13. Austin PC. An introduction to propensity score methods for reducing the effects of

- 384            confounding in observational studies. *Multivariate Behav Res.* 2011;46(3):399–424.
- 385    14.    Kislaya I, Peralta-Santos A, Borges V, Vieira L, Sousa C, Ferreira B, et al. Comparative  
386            complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-  
387            CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case-  
388            case study based on electronic health records. *Influenza Other Respi Viruses.*  
389            2023;17(3):1–10.
- 390    15.    Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, et al. Estimation of  
391            COVID-19 vaccine effectiveness against hospitalisation in individuals aged  $\geq 65$  years using  
392            electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March  
393            2022. *Eurosurveillance* [Internet]. 2022;27(30). Available from:  
394            <http://dx.doi.org/10.2807/1560-7917.ES.2022.27.30.2200551>
- 395    16.    Kislaya I, Sentís A, Starrfelt J, Nunes B, Martínez-Baz I, Nielsen KF, et al. Monitoring COVID-  
396            19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic  
397            health registries in  $\geq 65$  years old population in six European countries, October 2021 to  
398            November 2022. *Influenza Other Respi Viruses.* 2023;17(11):1–10.
- 399    17.    Fontán-Vela M, Kissling E, Nicolay N, Braeye T, Van Evercooren I, Hansen CH, et al. Relative  
400            vaccine effectiveness against COVID-19 hospitalisation in persons aged  $\geq 65$  years: results  
401            from a VEBIS network, Europe, October 2021 to July 2023. *Eurosurveillance.* 2024;29(1):1–  
402            8.
- 403    18.    Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al.  
404            Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5  
405            Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.

- 406 Influenza Other Respi Viruses. 2024;18(4):1–6.
- 407 19. Young-Xu Y, Snider JT, Mahmud SM, Russo EM, van Aalst R, Thommes EW, et al. High-dose  
408 influenza vaccination and mortality among predominantly male, white, senior veterans,  
409 United States, 2012/13 to 2014/15. Eurosurveillance. 2020;25(19):1–10.
- 410

medRxiv preprint doi: <https://doi.org/10.1101/2024.11.08.24316963>; this version posted November 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 1